Immunohistochemical pattern of p53 is a measure of TP53 mutation burden and adverse clinical outcome in myelodysplastic syndromes and secondary acute myeloid leukemia

Haematologica. 2016 Aug;101(8):e320-3. doi: 10.3324/haematol.2016.143214. Epub 2016 Apr 14.
No abstract available

Keywords: IHC; TP53; myelodysplastic syndromes.

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Cytogenetic Analysis
  • Female
  • Gene Frequency
  • Humans
  • Immunohistochemistry
  • Leukemia, Myeloid, Acute / diagnosis*
  • Leukemia, Myeloid, Acute / genetics
  • Leukemia, Myeloid, Acute / mortality
  • Male
  • Myelodysplastic Syndromes / diagnosis*
  • Myelodysplastic Syndromes / genetics
  • Myelodysplastic Syndromes / mortality
  • Neoplasms, Second Primary / diagnosis
  • Neoplasms, Second Primary / genetics
  • Neoplasms, Second Primary / mortality
  • Prognosis
  • Retrospective Studies
  • Survival Analysis
  • Tumor Suppressor Protein p53 / analysis*
  • Tumor Suppressor Protein p53 / genetics

Substances

  • TP53 protein, human
  • Tumor Suppressor Protein p53